Welcome to PsorVal.net | DermaSolve.net !

 

Your Source for Psor-Val | DermaSolve | Absorbase

 

 Serving Treatment Solutions for Psoriasis, Eczema, Dry Skin 

 

Providing News, Views, Tips and Tricks

along with great products for that   "Healthy You" 

 

Looking for Psor-Val Spray? Click here 


 

Now Shipping Psor-Val Spray World Wide

 International Clients - Click "We Ship Worldwide!"

MedWorm: Psoriasis

Circulating levels of inflammatory cytokines in patients with psoriasis vulgaris of different Chinese medicine syndromes (Fri, 19 Dec 2014)
Conclusions The expression profiles of cytokines in the circulation might not be necessarily identical for psoriatic patients with different CM syndromes. Accordingly, the serum concentrations of certain cytokines could potentially be used as the ancillary indices for the clinical classification of psoriatic CM syndromes. (Source: Chinese Journal of Integrative Medicine) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
>> read more

Replication of risk variants for psoriasis in a Southern European case‐control study: correlation with clinical subphenotypes (Thu, 18 Dec 2014)
This article is protected by copyright. All rights reserved. (Source: British Journal of Dermatology)
>> read more

The quest for an evidence‐based approach to surveillance for methotrexate‐related hepatotoxicity: Promise and perils (Thu, 18 Dec 2014)
This article is protected by copyright. All rights reserved. (Source: British Journal of Dermatology)
>> read more

A telephone‐based motivational interviewing intervention has positive effects on psoriasis severity and self‐management: a randomized controlled trial (Thu, 18 Dec 2014)
ORIGINAL ARTICLE, p 1458 (Source: British Journal of Dermatology)
>> read more

Effectiveness and safety of adalimumab in treating moderate to severe psoriasis patients with psoriatic arthritis in Taiwan (Thu, 18 Dec 2014)
Conclusion Patients with refractory psoriatic arthritis appeared to be responsive to adalimumab. The achievement rate of PsARC in our study was comparable to the efficacy reported in previous literature. Detection of antinuclear antibodies was not associated with the responsiveness in this trial, nor did it influence the potential for adverse effects. Adalimumab as a monotherapy is generally effective and safe. (Source: Dermatologica Sinica)
>> read more

The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic (Thu, 18 Dec 2014)
ConclusionsNon‐alcoholic fatty liver disease is very common among our cohort of patients with psoriasis, occurring in roughly 47% of patients. The more progressive form of the disease, NASH, is found in approximately one in five patients. Health care providers should be mindful of this association given the high prevalence of both NAFLD and NASH in this cohort of patients. (Source: Alimentary Pharmacology and Therapeutics) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
>> read more

Meta-analysis of the TNFAIP3 region in psoriasis reveals a risk haplotype that is distinct from other autoimmune diseases (Thu, 18 Dec 2014)
Authors: J Nititham, K E Taylor, R Gupta, H Chen, R Ahn, J Liu, M Seielstad, A Ma, A M Bowcock, L A Criswell, M Stahle & W Liao (Source: Genes and Immunity)
>> read more

Severe erytrodermic psoriasis in child twins: from clinical-pathological diagnosis to treatment of choice through genetic analyses: two case reports (Wed, 17 Dec 2014)
Conclusion: Pediatric erythroderma may pose a great challenge as a potentially life-threatening condition causing extreme distress in children, parents and pediatricians. In young patients it is mandatory to establish correct clinical and instrumental procedures, possibly supplemented by genetic analyses such as those we required, in order to determine an effective and safe therapy in terms of cost-benefit and put patients and family in the best condition to perform common daily activities. (Source: BMC Research Notes)
>> read more

Psoriatic arthritis: current therapy and future approaches (Wed, 17 Dec 2014)
PsA is a systemic inflammatory condition that affects 20–30% of patients with psoriasis. It is characterized by potential involvement of diverse tissues, including peripheral and axial joints, enthesitis, dactylitis and skin and nail disease. The degree of involvement in each domain can vary over time in individual patients and can differ substantially between PsA patients. The clinical heterogeneity along with the varying extent of severity and activity can pose significant challenges to treatment. Although some studies had suggested immunopathophysiological similarities between PsA and RA, more recently important distinctions have been defined. Similarly, although some immunomodulatory therapies have proved effective for both PsA and RA, recent data suggest distinct responses to ce...
>> read more

Childhood-onset PsA in Down syndrome with psoriasis susceptibility variant CARD14 rs11652075 (Wed, 17 Dec 2014)
(Source: Rheumatology)
>> read more

 

Scan our QR Code to your Smart Phone / iPhone Users download QR Reader from Tap Media http://www.TapMedia.co.uk 

Real Time Web Analytics


International Clients, After adding products to Cart - Refresh your browser if you do not see the "International Checkout" Button

Psor-Val Zinc Spray, DermaSolve Psoriasis Care Products and

Absorbase Cream for Moisturizing Skin Care.

 

Treatment Solutions and Products for Psoriasis, Eczema, Dry Skin. Natural Care for that Healthy You!